An economic perspective on policy to reduce antimicrobial resistance
References (37)
- et al.
A major outbreak of methicillin resistant Staphylococcus aureus caused be a new phage-type (EMRSA-16)
Journal of Hospital Infection
(1995) - et al.
What will it take to stop physicians from prescribing antibiotics in acute bronchitis?
Lancet
(1995) Sulphur abatement policy
Implications of cost differentials
Energy Policy
(1993)- et al.
The Clean Air Act's sulfur dioxide emissions market: estimating the costs of regulatory and legislative intervention
Resource and Energy Economics
(1995) The Oregon experiment
Report of the ASM task force on antibiotic resistance. Antimicrobial Agents and Chemotherapy
(1995)- et al.
Transactors, property rights and competition in the NHS market
Counting the Cost of Global Warming
(1992)A spoonful of oil makes the medicine unwanted
Independent
(1996)Superbug
Priority Setting: The Health Care Debate
(1996)
Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?
Health Economics
(1996)
Growth in the use of antibiotics in the community in England and Scotland in 1980–1993
British Medical Journal
(1996)
Strained Mercy: The Economics of Canadian Health Care
(1984)
Mutating microbes
Independent
(1995)
Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals
A challenge to hospital leadership
Journal of the American Medical Association
(1996)
The Demand for Health: A Theoretical and Empirical Investigation
(1972)
Economic incentives for optimal sulfur abatement in Europe
Energy Sources
(1995)
Cited by (0)
Copyright © 1998 Published by Elsevier Ltd.